(19)
(11) EP 1 542 609 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.02.2013 Bulletin 2013/08

(45) Mention of the grant of the patent:
14.11.2012 Bulletin 2012/46

(21) Application number: 03749229.5

(22) Date of filing: 29.08.2003
(51) International Patent Classification (IPC): 
A61K 38/21(2006.01)
A61K 35/00(2006.01)
A61K 39/00(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/US2003/027125
(87) International publication number:
WO 2004/019886 (11.03.2004 Gazette 2004/11)

(54)

Pharmaceutical compositions comprising Interferon beta for use in treating melanoma

Zusammensetzungen enthaltend Beta-Interferon zur Verwendung bei der Behandlung des Melanoms

Compositions comprenant l'Interféron bêta pour leur utilisation dans le traitement du mélanome


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 29.08.2002 US 407492 P

(43) Date of publication of application:
22.06.2005 Bulletin 2005/25

(73) Proprietor: CytoCure LLC
Beverly, MA 01915 (US)

(72) Inventors:
  • DURDA, Paul, J.
    Needham, MA 02492-3206 (US)
  • KURNICK, James, T.
    Quincy, MA 02169 (US)
  • Dunn, Ian, S.
    Sydney, New South Wales (AU)

(74) Representative: Vossius & Partner 
Siebertstrasse 4
81675 München
81675 München (DE)


(56) References cited: : 
EP-A1- 0 536 520
US-A- 4 737 462
US-B1- 6 710 086
EP-A2- 0 835 661
US-A1- 2001 042 551
   
  • MAKOTO ODAKA ET AL: "Eradication of Intraperitoneal and Distant Tumor by Adenovirus-mediated Interferon-ß Gene Therapy Is Attributable to Induction of Systemic Immunity" CANCER RESEARCH, vol. 61, 15 August 2001 (2001-08-15), pages 6201-6212, XP002586103
  • ZHONGYUN DONG ET AL.: "Suppression of Angiogenesis, Tumorigenicity, and Metastasis by Human Prostate Cancer Cells Engineered to Produce Interferon-ß" CANCER RESEARCH, vol. 59, 10 February 1999 (1999-02-10), pages 872-879, XP002586104
  • JOHN J. RINEHART ET AL.: "Phase I/II Trial of Interferon-ß-Serine in Patients with Renal Cell Carcinoma; Immunological and Biological Effects" CANCER RESEARCH, vol. 47, 1 May 1987 (1987-05-01), pages 2481-2485, XP002586105
  • SENSI MARIALUISA ET AL: "Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.92.12.5674, vol. 92, no. 12, 1 January 1995 (1995-01-01), pages 5674-5678, XP002143225 ISSN: 0027-8424
  • KAWAKAMI Y ET AL: "CLONING OF THE GENE CODING FOR A SHARED HUMAN MELANOMA ANTIGEN RECOGNIZED BY AUTOLOGOUS T CELLS INFILTRATING INTO TUMOR" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.91.9.3515, vol. 91, no. 9, 26 April 1994 (1994-04-26) , pages 3515-3519, XP000770221 ISSN: 0027-8424
  • MATEO ET AL: "An HLA-A2 polyepitope vaccine for melanoma immunotherapy" J IMMUNOL., vol. 7, no. 1, October 1999 (1999-10), pages 4058-4063, XP002587571
  • BROUWENSTIJN N ET AL.: "Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage." BR J CANCER, vol. 12, 1997, pages 1562-1566, XP002587572
  • MASCI PAUL ET AL: "Malignant melanoma: treatments emerging, but early detection is still key.", CLEVELAND CLINIC JOURNAL OF MEDICINE JUL 2002 LNKD- PUBMED:12109636, vol. 69, no. 7, July 2002 (2002-07), pages 529 , 533-534 , 536, ISSN: 0891-1150
  • SMITS A: "Low-grade gliomas: clinical and pathobiological aspects.", HISTOLOGY AND HISTOPATHOLOGY JAN 2002 LNKD- PUBMED:11813876, vol. 17, no. 1, January 2002 (2002-01), pages 253-260, ISSN: 0213-3911
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).